Comparative Pharmacology
Head-to-head clinical analysis: ALTACE versus CAPOTEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALTACE versus CAPOTEN.
ALTACE vs CAPOTEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Angiotensin-converting enzyme inhibitor; inhibits ACE, preventing conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion.
Competitive inhibitor of angiotensin-converting enzyme (ACE), preventing conversion of angiotensin I to angiotensin II, leading to decreased vasoconstriction, reduced aldosterone secretion, and increased plasma renin activity.
2.5-5 mg orally once daily initially, titrated to 10-20 mg once daily; maximum 20 mg/day
50 mg orally three times daily initially; maintenance 50-100 mg three times daily; maximum 450 mg/day.
None Documented
None Documented
Ramiprilat: 13–17 hours (prolonged in renal impairment, up to 50 hours in severe renal insufficiency; multiple doses: 45–60 hours effective half-life due to tissue binding)
Terminal elimination half-life is approximately 1.9 hours in healthy subjects, but prolonged in heart failure (up to 3-4 hours) and renal impairment (up to 5-10 hours).
Renal: 60% (30% as ramiprilat, 30% as metabolites); Fecal: 40% (unabsorbed drug and biliary metabolites)
Primarily renal (approximately 60-75% as unchanged drug and metabolites) and biliary/fecal (approximately 20%).
Category C
Category C
ACE Inhibitor
ACE Inhibitor